Pneumococcal vaccine response in cirrhosis and liver transplantation

Timothy M McCashland, L. C. Preheim, Martha J. Gentry-Nielsen

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Cirrhosis is a major risk factor for severe pneumococcal infection, and patients evaluated for liver transplantation routinely receive pneumococcal vaccine. This study followed serologic antibody levels of 45 adults evaluated for transplantation and 13 age-matched control subjects. All received 23-valent pneumococcal polysaccharide vaccine (PPS). Serum anti-PPS levels and antibodies specific for capsular types 3 and 23 were measured by ELISA before and 1 and 6 months after vaccination. Antibody levels for the 25 patients who received transplants also were measured immediately before and 3 months after transplantation. Control subjects had higher IgG responses to the whole vaccine, whereas patients appeared to produce more IgM and IgA. IgA, and possibly IgM levels, also declined faster in patients than in control subjects. All anti-PPS levels were at or below prevaccination baselines by 3 months after transplantation. These data suggest that vaccination with PPS may not be effective for patients during and after liver transplantation.

Original languageEnglish (US)
Pages (from-to)757-760
Number of pages4
JournalJournal of Infectious Diseases
Volume181
Issue number2
DOIs
StatePublished - Mar 15 2000

Fingerprint

Pneumococcal Vaccines
Liver Transplantation
Fibrosis
Transplantation
Immunoglobulin A
Immunoglobulin M
Antibodies
Vaccination
Pneumococcal Infections
Vaccines
Immunoglobulin G
Enzyme-Linked Immunosorbent Assay
Transplants
Serum

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Pneumococcal vaccine response in cirrhosis and liver transplantation. / McCashland, Timothy M; Preheim, L. C.; Gentry-Nielsen, Martha J.

In: Journal of Infectious Diseases, Vol. 181, No. 2, 15.03.2000, p. 757-760.

Research output: Contribution to journalArticle

McCashland, Timothy M ; Preheim, L. C. ; Gentry-Nielsen, Martha J. / Pneumococcal vaccine response in cirrhosis and liver transplantation. In: Journal of Infectious Diseases. 2000 ; Vol. 181, No. 2. pp. 757-760.
@article{3b420f5536004d17981ad0eaf2fa4f3e,
title = "Pneumococcal vaccine response in cirrhosis and liver transplantation",
abstract = "Cirrhosis is a major risk factor for severe pneumococcal infection, and patients evaluated for liver transplantation routinely receive pneumococcal vaccine. This study followed serologic antibody levels of 45 adults evaluated for transplantation and 13 age-matched control subjects. All received 23-valent pneumococcal polysaccharide vaccine (PPS). Serum anti-PPS levels and antibodies specific for capsular types 3 and 23 were measured by ELISA before and 1 and 6 months after vaccination. Antibody levels for the 25 patients who received transplants also were measured immediately before and 3 months after transplantation. Control subjects had higher IgG responses to the whole vaccine, whereas patients appeared to produce more IgM and IgA. IgA, and possibly IgM levels, also declined faster in patients than in control subjects. All anti-PPS levels were at or below prevaccination baselines by 3 months after transplantation. These data suggest that vaccination with PPS may not be effective for patients during and after liver transplantation.",
author = "McCashland, {Timothy M} and Preheim, {L. C.} and Gentry-Nielsen, {Martha J.}",
year = "2000",
month = "3",
day = "15",
doi = "10.1086/315245",
language = "English (US)",
volume = "181",
pages = "757--760",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Pneumococcal vaccine response in cirrhosis and liver transplantation

AU - McCashland, Timothy M

AU - Preheim, L. C.

AU - Gentry-Nielsen, Martha J.

PY - 2000/3/15

Y1 - 2000/3/15

N2 - Cirrhosis is a major risk factor for severe pneumococcal infection, and patients evaluated for liver transplantation routinely receive pneumococcal vaccine. This study followed serologic antibody levels of 45 adults evaluated for transplantation and 13 age-matched control subjects. All received 23-valent pneumococcal polysaccharide vaccine (PPS). Serum anti-PPS levels and antibodies specific for capsular types 3 and 23 were measured by ELISA before and 1 and 6 months after vaccination. Antibody levels for the 25 patients who received transplants also were measured immediately before and 3 months after transplantation. Control subjects had higher IgG responses to the whole vaccine, whereas patients appeared to produce more IgM and IgA. IgA, and possibly IgM levels, also declined faster in patients than in control subjects. All anti-PPS levels were at or below prevaccination baselines by 3 months after transplantation. These data suggest that vaccination with PPS may not be effective for patients during and after liver transplantation.

AB - Cirrhosis is a major risk factor for severe pneumococcal infection, and patients evaluated for liver transplantation routinely receive pneumococcal vaccine. This study followed serologic antibody levels of 45 adults evaluated for transplantation and 13 age-matched control subjects. All received 23-valent pneumococcal polysaccharide vaccine (PPS). Serum anti-PPS levels and antibodies specific for capsular types 3 and 23 were measured by ELISA before and 1 and 6 months after vaccination. Antibody levels for the 25 patients who received transplants also were measured immediately before and 3 months after transplantation. Control subjects had higher IgG responses to the whole vaccine, whereas patients appeared to produce more IgM and IgA. IgA, and possibly IgM levels, also declined faster in patients than in control subjects. All anti-PPS levels were at or below prevaccination baselines by 3 months after transplantation. These data suggest that vaccination with PPS may not be effective for patients during and after liver transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0034051560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034051560&partnerID=8YFLogxK

U2 - 10.1086/315245

DO - 10.1086/315245

M3 - Article

VL - 181

SP - 757

EP - 760

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 2

ER -